# Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13

> **NCT05408429** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 356 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** 20-valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT05408429
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-24
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05408429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05408429, "Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05408429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*